Nanopublication

ID

http://purl.org/np/RAgxmbO2xXrnagG8Vn_g96GE4sXNQWgfx0nUt2vFQAm7Q
Formats

Content

@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://www.w3.org/ns/prov#> .
@prefix this: <http://purl.org/np/RAgxmbO2xXrnagG8Vn_g96GE4sXNQWgfx0nUt2vFQAm7Q> .
@prefix sub: <http://purl.org/np/RAgxmbO2xXrnagG8Vn_g96GE4sXNQWgfx0nUt2vFQAm7Q#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1040> bl:category bl:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_1040>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB08935>;
    rdfs:label "gazyva obinutuzumab is a cd2 directed cytolytic antibody and is indicated in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia 1 14 in combination with bendamustine followed by gazyva monotherapy for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen 1 14 in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma 1 14 gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia see clinical studies 14 1 gazyva in combination with bendamustine followed by gazyva monotherapy is indicated for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab containing regimen see clinical studies 14 2 gazyva in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission is indicated for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma see clinical studies 14 2";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB08935> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "JaAfyOZO/oMwBFr+loueYTOa71hFJ8DZQO6lZHQIPXT9Rh3UZc2Fwp9MT0UAwaGSiSFBfRp+TrZbVeFzrWCbe7dc2ChsBm1YEY6SrddZ+lPe6NOdNW1ZulY+JfW9YUD6N+v8KWRAbrdwEJvtI96s+YNkYqp9sFjZuayDFVET0xs=";
    npx:hasSignatureTarget this: .
  
  this: dcterms:created "2021-07-03T15:27:24.557+02:00"^^xsd:dateTime;
    dcterms:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}